The Ex-Humira Engine Is Firing on All Cylinders, But a +4% Gap That Faded to Flat Tells You the Price Already Knows It — Initiating at Hold

Results vs. Consensus

Q2 2025 Scorecard

Year-Over-Year Comparison

Sequential (QoQ) Context

Q1→Q2 sequential gains are partly seasonal — Q1 carries the U.S. gross-to-net "donut hole" reset and Part D redesign step-down that depresses first-quarter net pricing across the industry — so the +20.7% EPS jump overstates the underlying trajectory. The YoY frame (+12.1% adjusted EPS) is the cleaner read.

Quality of Beat

Revenue: The $400M revenue overachievement was concentrated in the right places — Skyrizi and Rinvoq in immunology and a broad-based neuroscience beat — not in one-time items or stocking. Reported growth of 6.6% versus operational growth of 6.5% means foreign exchange was a negligible (modestly favorable) tailwind; this was an organic-demand beat. The single most important number in the release is not on the scorecard: the ex-Humira platform grew 22%, which is the growth rate that matters once Humira is fully in the rear-view.

Margins: Adjusted gross margin of 84.4% and an adjusted operating margin of 44.3% both reflect a 5.3-point unfavorable hit from acquired IPR&D run through the adjusted P&L. Strip the IPR&D and the underlying operating margin is ~49.6% — firmly in the high-40s/~50% range that characterizes AbbVie at scale. The mix is also quietly improving: the highest-margin franchises (immunology, neuroscience) are growing fastest, and the lowest-incremental-margin one (aesthetics) is shrinking.

EPS: The 12.1% YoY adjusted-EPS growth is fully operational. The GAAP-to-adjusted gap is wide ($0.52 GAAP vs. $2.97 adjusted) and almost entirely attributable to amortization of acquired intangibles (the Allergan/Cerevel/ImmunoGen legacy) plus the $0.42 IPR&D charge. The 32.5% GAAP EPS decline looks alarming in isolation but is a function of acquisition accounting, not deteriorating economics — a perennial feature of AbbVie's serial-acquirer model that the market has long since learned to look through.

Segment Performance

Therapeutic-Area Revenue Mix — Q2 2025

Immunology — The Engine Has Two New Cylinders, One Fading

Immunology delivered $7.631B (+9.5% reported), but the headline understates the underlying transformation. Skyrizi grew 61.8% operationally to $4.423B and Rinvoq grew 41.2% operationally to $2.028B, while Humira fell 58.2% operationally to $1.180B on biosimilar exclusionary formularies. The crossover is decisive: the two growth assets added roughly $2.5B of YoY revenue while Humira shed roughly $1.6B — the platform is now growing through the largest patent cliff in pharmaceutical history. Management raised the Skyrizi FY25 guide by $600M to $17.1B (split, per the CFO, $11.3B psoriatic / $5.8B IBD) and lifted Rinvoq's trajectory; together they are pacing past $25B for the year.

"Skyrizi and Rinvoq... are now on pace to deliver more than $25 billion in combined sales this year, well above our initial expectations." — Rob Michael, Chairman & CEO

The durability question — how long can a seven-year-old psoriasis brand keep gaining share? — got a confident answer. Management emphasized that Skyrizi is "still gaining in-play share" in psoriasis seven years post-launch ("really not been observed on a brand this big over that amount of time") and that the IBD launches (Crohn's, ulcerative colitis) are early, with the Skyrizi+Rinvoq portfolio capturing one of every two in-play Crohn's patients and one of three in UC.

Assessment: This is the crux of the bull case and it is intact. The risk is no longer the Humira cliff — that is a known, shrinking number ($3B U.S. for the full year, guided down $500M) — it is whether Skyrizi/Rinvoq growth decelerates as they lap easier comps and as STELARA and TREMFYA biosimilars/competitors mature in IL-23. Management argued the IL-23 class still holds only single-digit total-patient share in IBD (versus 60% in psoriasis today), implying years of headroom. We find that credible. The franchise is best-in-class; the only debate is the multiple you pay for it.

Neuroscience — The Second Engine the Market Underweights

Neuroscience grew 24.2% reported to $2.683B, with every brand beating: Vraylar $900M (+16.3%), Botox Therapeutic $928M (+14.2%), Ubrelvy $338M (+47.2%), Qulipta $267M (+76.9%), and Vyalev $98M (+56% sequentially) in Parkinson's. Management says AbbVie will be "the largest neuroscience company in the industry next year." The growth is volume-and-promotion driven, not price — the cleanest kind — and the company is leaning further in, ramping U.S. Vyalev investment and preparing a sales-force expansion for tavapadon (oral Parkinson's) ahead of launch.

"Every brand exceeded expectations in neuroscience this quarter, and we're going to keep fueling that engine." — Rob Michael, Chairman & CEO

The migraine franchise is now #1 across all three segments (acute with Ubrelvy, prevention with Qulipta, chronic with Botox), and the head-to-head TEMPLE study showing Qulipta beat topiramate on both discontinuations and migraine-day reduction sets up a share-take story against the dominant generic incumbent.

Assessment: Neuroscience is the most underappreciated part of the story and a genuine second growth pillar — psychiatry, the industry's leading migraine portfolio, and an emerging multi-billion-dollar Parkinson's franchise (Vyalev + Duodopa + tavapadon). At 17% of revenue and growing mid-20s, it is increasingly the swing factor in whether AbbVie compounds high-single-digits or low-double-digits through the decade. This is a thesis-supporting positive that, notably, the flat stock reaction did not reward.

Oncology — The Drag Inside a Growth Story

Oncology grew just 2.6% to $1.676B — the weakest of the four portfolios on a growth basis (Aesthetics being the only one in decline). Imbruvica fell 9.5% to $754M on continued CLL competitive pressure, masking double-digit growth from Venclexta ($691M, +8.3% operational), Elahere ($159M), and Epkinly. The newest launch, Emrelis (c-Met ADC in non-small-cell lung cancer), is just beginning. The R&D narrative is more compelling than the revenue: management leaned hard into a next-generation ADC platform (Temab-A posted a 63% ORR in EGFR-mutated NSCLC) and a three-asset multiple-myeloma T-cell-engager strategy.

"IMBRUVICA global sales were $754 million, down 9.5%, reflecting continued competitive dynamics in CLL, partially offset by higher persistency rates for existing patients." — Jeff Stewart, Chief Commercial Officer

Assessment: Oncology is the portfolio where AbbVie has the least to show today for its ambitions. The Imbruvica decline is a real drag and will persist; the offsetting next-gen assets (ADCs, trispecifics) are mostly 2027+ stories. Encouragingly, the One Big Beautiful Bill Act's expanded orphan-drug exemption now shields Venclexta from IRA negotiation — a modest but real positive. Net: oncology is neutral-to-slightly-negative for the near-term model and an option on the back half of the decade.

Aesthetics — The Part of the Thesis That Isn't Working

Aesthetics fell 8.1% to $1.279B, with Botox Cosmetic at $692M and Juvederm at $260M both declining operationally. Management attributed the weakness to "economic challenges and lower overall consumer sentiment," with dermal fillers ("patients are more sensitive to the price points of the fillers versus the toxins") and an emerging "natural look" / fear-of-overfilling sentiment shift hitting the filler market hardest.

"I do think it's more chronic than we've seen before... the longer-term impact on the pocketbook of the consumers has just been more chronic, and we've seen that across even just recent reports on luxury good items." — Jeff Stewart, Chief Commercial Officer

The candor here is notable and, frankly, less reassuring than in prior quarters. Pressed on why this downturn is different, management conceded it is "more chronic" than past soft patches and falls back on market-share stability (Botox remains the clear category leader) rather than market growth, which is what is actually broken. The defense rests on long-term penetration optionality and a 2026 product catalyst (TrenibotE, a short-acting toxin).

Assessment: Aesthetics is the clearest bear pillar. It is a discretionary, cash-pay, consumer-cyclical business bolted onto an otherwise insulated pharma franchise, and it is in outright decline with management signaling the headwind is structural-for-now rather than transient. At 8% of revenue it does not break the thesis, but it removes a growth leg the market paid up for when AbbVie bought Allergan, and it is a live reason the stock will not re-rate higher until it troughs. We treat 2026 as the earliest plausible stabilization and assign no near-term recovery credit.

Key Topics & Management Commentary

Overall Management Tone: The call was confident and well-rehearsed, with management leaning forward on the immunology and neuroscience growth engines and on a prolific business-development cadence (30+ deals since the start of last year). The posture was most assured on the ex-Humira platform and visibly more defensive on aesthetics, where the answers shifted from prior quarters' "this is cyclical and resilient" to a candid "this is more chronic than we've seen." On guidance, the framing was deliberately measured — raising for the second time while declining to refresh long-term targets — consistent with a team that prefers to under-promise on a stock the market already prices for execution.

1. Skyrizi + Rinvoq: Past $25B and Still Taking Share

The single most important commercial fact in the quarter is that the two growth drivers are now pacing past $25B combined for FY25, above AbbVie's own initial expectations, with the Skyrizi guide raised $600M to $17.1B. Management's argument for durability rests on three legs: continued in-play share gains in mature psoriasis (seven years post-launch), early-innings IBD penetration, and a head-to-head data moat.

"It's been 7 years since the initial psoriasis approval, and we are still gaining in-play share, really not been observed on a brand this big over that amount of time." — Jeff Stewart, Chief Commercial Officer

The CFO disaggregated the $600M Skyrizi raise as ~$400M IBD / ~$200M psoriatic, putting the implied FY split at $11.3B psoriatic and $5.8B IBD — useful texture confirming that the newer IBD indications are now the marginal growth driver.

Assessment: This is the load-bearing wall of the entire investment case, and it is solid. The combined $25B+ run-rate validates that AbbVie has successfully replaced Humira's peak with two assets that are earlier in their lifecycle and arguably better positioned. The watch item is the eventual deceleration math, not any present weakness.

2. Humira: The Cliff Is Now Just a Number

Humira fell 58.2% operationally to $1.18B and management guided U.S. Humira down a further $500M to $3B for the year as more plans adopt exclusionary formularies in H2. Critically, much of the lost Humira volume is not leaking to biosimilars but converting upward to Skyrizi and Rinvoq — a dynamic AbbVie engineered with its Sequence head-to-head trial.

"We did see movement from Humira—not all of it went to the biosimilars. Some went to... Skyrizi and Rinvoq." — Jeff Stewart, Chief Commercial Officer

Assessment: The Humira cliff has gone from existential risk to a manageable, decaying line item. The within-franchise upgrade dynamic is the best possible outcome — AbbVie is cannibalizing its own legacy asset with higher-value successors. This is thesis-confirming and largely de-risked.

3. The Second Guidance Raise — Measured, Not Maximal

Management raised FY25 for the second time: revenue +$800M to ~$60.5B (now +$1.5B since the year began) and adjusted EPS +$0.21 to $11.88–$12.08. Notably, the EPS guide explicitly does not include any estimate for acquired IPR&D beyond Q2 — so the headline range is a "clean" operating number that future deals will reduce.

"We are raising guidance for the second time. We now expect full year revenue of $60.5 billion... We have now raised our revenue guidance by $1.5 billion since the start of the year." — Rob Michael, Chairman & CEO

Assessment: A second raise is unambiguously good. But the magnitude is measured, and management pointedly declined to refresh long-term guidance despite analyst prompting (see Q&A). For a stock already trading at a full multiple, "good but in-line-to-slightly-better" guidance is exactly the profile that produces a gap-up-then-fade reaction.

4. Aesthetics: Management Concedes the Headwind Is "More Chronic"

The most consequential tonal shift on the call was on aesthetics. After several quarters of framing the downturn as a transient, recession-style soft patch with resilient brands, management this quarter conceded the consumer headwind is "more chronic" and acknowledged a sentiment shift toward a "natural look" that is specifically pressuring dermal fillers.

"Nothing you have said is particularly encouraging. In the past, the company has pointed to past periods of uncertainty and the resilience these brands have had... why is this economic uncertainty different than in the past?" — Steve Scala, TD Cowen (analyst question)

Management's response leaned on market-share stability and long-term penetration optionality rather than near-term recovery, and pointed to the 2026 TrenibotE launch as the category catalyst. CEO Rob Michael reframed it as "market growth versus market share," noting share performance "has been stable" even as the category contracts.

Assessment: When management stops defending the cyclical-recovery narrative and pivots to "our share is holding in a shrinking market," that is a tacit admission the timeline has slipped. This is the single most bearish exchange on the call and a key reason we are not initiating at Outperform.

5. Business Development: 30+ Deals and an Entry Into Obesity

Management framed capital allocation around building the next decade rather than plugging a near-term hole — AbbVie has executed 30+ BD transactions since the start of last year, including the closed Gubra amylin deal (obesity entry), the planned Capstan acquisition (in vivo CAR-T for immunology), the ISB-2001 trispecific (myeloma), and the ADARx siRNA collaboration. The $0.42 IPR&D charge this quarter is the visible cost of that cadence.

"We have executed more than 30 business development transactions since the beginning of last year... without any significant LOEs this decade, we have the flexibility to invest more in R&D to continue to acquire external innovation." — Rob Michael, Chairman & CEO

Assessment: The BD machine is a genuine differentiator and the right strategy — with no major LOE this decade, AbbVie can fund pipeline optionality out of cash flow. The cost is a perpetually noisy GAAP line and recurring IPR&D drag on adjusted EPS. For a Hold thesis this is a wash: it builds long-duration value while suppressing the near-term reported number the market anchors on.

6. The Obesity Optionality — Aesthetics Footprint as a Channel

One of the more strategically interesting threads was how AbbVie intends to leverage its global aesthetics commercial footprint to distribute obesity drugs. Management observed that cash-pay weight-loss had become the #2 revenue driver in aesthetics practices (behind toxins) before compounding dynamics faded, and framed the Gubra amylin asset as a way to recapture that demand directly through clinics.

"We know that... that's just going to be ongoing demand... we think we're very uniquely positioned to be able to deliver that to the aesthetic clinics around the world." — Jeff Stewart, Chief Commercial Officer

Assessment: This is real optionality but a back-half-of-the-decade story with no near-term P&L impact, and it enters a brutally competitive category dominated by incumbents with massive scale leads. We assign it option value, not base-case credit. It is, however, a creative reframing of the otherwise-struggling aesthetics asset as a distribution channel.

7. Pricing & Gross-to-Net: A Back-Half Step-Down Telegraphed

The CFO was unusually direct that H1 Skyrizi pricing was favorable due to "some price gating items that were unique" and a Part D redesign impact weighted to the back half — explicitly guiding that "you will see some negative price in the back half of the year" for Skyrizi, with full-year pricing neutral and long-term low-single-digit.

"We do expect on an overall basis that pricing to be neutral for Skyrizi... You will see some negative price in the back half of the year." — Scott Reents, Chief Financial Officer

Assessment: A useful piece of conservatism that the raised guide already embeds. It tempers any temptation to extrapolate H1's strong net-revenue trajectory linearly into H2 — the volume story is intact, but the price tailwind reverses. This is part of why the second raise was measured rather than maximal.

8. Tariffs & Section 232: Insulated for 2025, Unquantified Beyond

On the EU/pharma tariff overhang, management said AbbVie is "fairly insulated" for 2025 given inventory-management actions and a broad U.S. manufacturing network (11 API/biologics/toxin/small-molecule sites, with Skyrizi made domestically), and pointed to the previously-announced $10B U.S. capital-investment program (four new sites). But it declined to quantify any 2026+ impact pending the Section 232 investigation outcome.

"As it relates to '25, we're fairly insulated from any impact this year given inventory management actions. But... we're not going to speculate on the longer-term impact." — Rob Michael, Chairman & CEO

Assessment: Adequately handled and not a 2025 issue. The 2026 tail risk is real but unquantifiable today; management's "we don't expect our exposure to be outsized relative to peers" is a reasonable holding statement. We treat tariffs as a mild, latent overhang rather than an active thesis driver.

9. R&D Catalysts: Alopecia, Vitiligo, and the Rinvoq "Third Wave"

R&D leadership flagged a deep set of near-term readouts, anchored by the just-announced Phase III alopecia areata win for Rinvoq (54% of patients on the 30mg dose reached 80%+ scalp coverage at 24 weeks — described as ~20 points above competing JAKs) and upcoming vitiligo Phase III data. Management frames these as a "third wave" of Rinvoq indications worth ~$2B in incremental peak sales, overlapping the existing derm/rheum call points.

"The collection of the next wave of indications would add approximately $2 billion to peak year sales for Rinvoq." — Jeff Stewart, Chief Commercial Officer

Assessment: These extend Rinvoq's runway into the late 2020s and reinforce that the immunology franchise has multi-year duration beyond the current indication set. Positive, but a 2027–2029 contributor — it supports the long-term thesis without changing the near-term setup that drives a Hold today.

Guidance & Outlook

The second raise of the year is the right kind — demand-led and concentrated in the structurally advantaged franchises (Skyrizi +$600M, neuroscience +$300M), partly offset by a faster Humira decline (−$500M). The CFO was explicit that the FY25 adjusted-EPS range excludes any acquired IPR&D incurred beyond Q2, meaning the guide is a clean operating figure that AbbVie's deal cadence will mechanically reduce as the year plays out — a feature of this management's framework, not a surprise.

Implied H2 ramp: The $11.88–$12.08 full-year midpoint of $11.98, against $2.46 (Q1) + $2.97 (Q2) = $5.43 reported in H1, implies ~$6.55 of adjusted EPS in H2, or roughly $3.26–$3.30 per quarter — squarely consistent with the explicit Q3 guide of $3.24–$3.28. The full-year revenue of ~$60.5B against H1's ~$28.8B implies ~$31.7B in H2, a modest sequential acceleration consistent with the Q3 ~$15.5B guide and continued Skyrizi/Rinvoq/neuroscience momentum, net of the telegraphed back-half Skyrizi price step-down.

Guidance style: Characteristically conservative. AbbVie has now raised twice and still declined to refresh its long-term targets despite direct analyst prompting, preferring to update those "at the appropriate time" (typically Q4/JPM). For a name priced for execution, this measured cadence is prudent but offers the stock little fresh fuel.

Analyst Q&A Highlights

STELARA Biosimilars and Whether They Threaten Skyrizi/Rinvoq

The opening question probed whether STELARA biosimilar entry would pressure Skyrizi/Rinvoq or, conversely, accelerate upgrades to them (as Humira biosimilarization partly did). Management characterized any STELARA-driven effect as minor, arguing Skyrizi's momentum is fundamentally data- and execution-driven rather than a biosimilar-displacement artifact.

Q: "I have a question regarding the impact of STELARA biosimilar on Skyrizi and Rinvoq... as you saw with HUMIRA biosimilar, people decided to not change to biosimilar, but to a more efficacious drug like Skyrizi and Rinvoq. How do you think about the impact... considering these 2 dynamics?"
— Mohit Bansal, Wells Fargo

A: "STELARA is still relatively early, and there are more interchangeable biosimilars... it was a much smaller drug because it's really just concentrated in GI. So it's difficult to sort of tease out exactly what movement we're seeing... net-net, I think the core momentum around Skyrizi and Rinvoq are simply related to just the outstanding data, the breadth of indications... if anything, it's a minor contributor."
— Jeff Stewart, Chief Commercial Officer

Assessment: Management answered directly and credibly — the Skyrizi/Rinvoq growth is share-gain-driven, not a one-time biosimilar windfall. The CEO's reinforcement that the Sequence head-to-head drove a "notable share inflection" before STELARA biosimilars even arrived supports the view that the engine runs on data, not competitor patent cliffs.

Confidence in the 2027 Skyrizi/Rinvoq Long-Term Targets

A recurring line of questioning pressed on the durability of the long-term Skyrizi (>$20B by 2027) and Rinvoq (>$11B) targets given both are already annualizing well above prior expectations, and whether management would refresh long-term guidance. Management declined to refresh now, signaling an update "at the appropriate time" while emphasizing it is tracking well ahead.

Q: "Skyrizi... it's annualizing at about $18 billion now. I know you have the 2027 guidance out there for over $20 billion. So just maybe help us think about that number and confidence there... And then... any thoughts on the latest tariff announcement regarding the EU?"
— Terence Flynn, Morgan Stanley

A: "We occasionally update the long-term guidance... around the time of the fourth quarter call... We do refresh long-term guidance. I'd say we're obviously tracking very well against the last long-term guidance we issued. And... when you look at Street expectations as well, they have come up, too... we'll update that long-term guidance at the appropriate time, but the momentum is clearly there."
— Rob Michael, Chairman & CEO

Assessment: A confident non-answer. Management is clearly tracking ahead of the >$20B/>$11B targets but is deliberately holding the upgrade for Q4/JPM. For the stock, this is the crux of the fade: the Street already knows the numbers are conservative, so deferring the refresh leaves no near-term upgrade catalyst even though the underlying trajectory is strong.

What Is Actually Driving the Skyrizi Upside — IBD vs. Derm

Analysts sought to decompose the Skyrizi raise between IBD and dermatology to gauge sustainability. The CFO provided unusually specific disaggregation, and the CEO used the question to pivot to a broader capital-allocation point about funding later-stage BD.

Q: "On Skyrizi... what in particular is driving this? Is it all IBD? Or are you also seeing upside to the derm indications as well? And then... should we think about this still being kind of the string of early stage or mid-stage deals? Or is there appetite to also look at later-stage assets...?"
— Chris Schott, JPMorgan

A: "That $600 million raise, $400 million of that you could think of as IBD, $200 million in psoriatic. So that's going to put the split of the 17.1 at 11.3 for psoriatic and 5.8 for IBD."
— Scott Reents, Chief Financial Officer

Assessment: The disaggregation is a tell that IBD is now the marginal driver — the newer, earlier-lifecycle indication carrying two-thirds of the raise. That is the most durable possible mix because IBD penetration is years behind psoriasis. On BD, the CEO kept the door open to larger deals while reaffirming the early/mid-stage focus, consistent with the "build the next decade" framing.

Vyalev Trajectory and the U.S. Parkinson's Launch

Questioning turned to whether the Vyalev raise was U.S.- or internationally-driven and what the OUS success implies for the upcoming U.S. ramp. Management attributed the strength to international core demand and reaffirmed the U.S. Medicare ramp is on track for late in the year.

Q: "On VYALEV... Should we think about that being primarily driven by U.S. or OUS? ...has the OUS success sort of changed the way you think about the U.S. launch there?"
— Carter Gould, Cantor

A: "We're super pleased with the launch in Vyalev... the raise really is largely related to just the core demand [internationally]... we're very confident that we're going to start to see the Medicare ramp in the U.S. start here in the latter part of the year... a $400 million running rate in the international market, very impressive."
— Jeff Stewart, Chief Commercial Officer

Assessment: The Vyalev story is tracking ahead internationally with the larger U.S. opportunity still in front of it — a clean, additive growth vector for neuroscience. This is the kind of optionality the market is not yet paying much for, and it reinforces our view that neuroscience is the under-modeled engine.

Aesthetics: Why This Downturn Is Different

The most pointed exchange of the call directly challenged management's prior "these brands are resilient" framing, asking why the current weakness is lingering longer than past soft patches and whether competition is also eroding the franchises. Management conceded the headwind is "more chronic" and leaned on share stability rather than category recovery.

Q: "Nothing you have said is particularly encouraging. In the past, the company has pointed to past periods of uncertainty and... the resilience these brands have had during that period. So... why is this economic uncertainty different than in the past? This one seems to be lingering longer than in past soft periods?"
— Steve Scala, TD Cowen

A: "I think there is a difference between this and some other areas where we've had some economic uncertainty. It's been sort of more short-term recessionary issues. I think the longer-term impact on the pocketbook of the consumers has just been more chronic... I do think it's more chronic than we've seen before."
— Jeff Stewart, Chief Commercial Officer

Assessment: This is the exchange that best explains the flat stock reaction. Management's own characterization shifted from cyclical-and-resilient to "more chronic," which removes the near-term recovery optionality the market had been carrying for aesthetics. The CEO's follow-up reframing to "market growth versus market share" is a tacit concession that the category, not AbbVie's position within it, is the problem — and that is harder to fix on a near-term timeline.

IRA Price Negotiation and the GLP-1 Effect on Aesthetics

Questioning paired the upcoming IRA negotiation round (Vraylar is in this cycle) with the net effect of GLP-1 weight-loss drugs on Botox/filler demand. Management deflected on the active negotiation (price public in November) but disclosed a favorable IRA change and called the GLP-1 effect net-neutral.

Q: "I have a question on IRA price negotiation. You guys have a horse in the race again with Vraylar... There have been investor fears that this next round of negotiations will be worse than last year... And then... the impact from the GLP-1s on BOTOX and dermal fillers, what's the latest?"
— Tim Anderson, Bank of America

A: "As we go through these negotiations, we don't publicly comment for obvious reasons... one important notable change as part of the One Big Beautiful Bill Act is the expansion of the IRA orphan drug exemption... we would not expect Venclexta to be negotiated. And regarding the GLP-1s... it's really a net neutral."
— Rob Michael, Chairman & CEO / Jeff Stewart, CCO

Assessment: Two small positives netted out of one question — the Venclexta orphan-exemption shields a real future oncology cash flow from IRA, and GLP-1s are not the aesthetics culprit (deflating one bear narrative even as the macro one is confirmed). Management dodged the Vraylar negotiation specifics, which is standard and not a red flag.

What They're NOT Saying

1. No refreshed long-term Skyrizi/Rinvoq guidance: Despite both assets annualizing well above the >$20B/>$11B 2027 targets and repeated analyst prompting, management held the upgrade for "the appropriate time." The numbers are clearly conservative — but withholding the refresh removes the single most obvious near-term re-rating catalyst, which is part of why the stock faded.
2. No timeline for an aesthetics inflection: Management would not put a date on when aesthetics returns to growth, retreating to market-share stability and a 2026 TrenibotE catalyst. The absence of a "we expect stabilization in [period]" is itself the signal — they don't have visibility to one.
3. No quantification of 2026 tariff / Section 232 exposure: Insulated for 2025, but every forward question was deferred to the pending 232 outcome. "Not outsized relative to peers" is a relative comfort, not an absolute number, and leaves a real but unsized 2026 overhang.
4. Quiet on Imbruvica's terminal trajectory: The 9.5% decline was acknowledged but not framed with a floor or stabilization path. With CLL competition structural, the market is left to extrapolate continued erosion of a still-meaningful $3B+ annual franchise.
5. Limited color on the GAAP-to-adjusted bridge sustainability: With 30+ BD deals driving recurring IPR&D and a $0.42 quarterly charge, management did not address how investors should think about the steady-state IPR&D run-rate that the adjusted number absorbs each year — a structurally noisy element of the EPS the stock is valued on.
6. No specifics on obesity competitive positioning: Management was enthusiastic about the amylin/aesthetics-channel obesity strategy but offered no clinical differentiation data versus entrenched GLP-1 incumbents — appropriate given the early stage, but a reminder this is option value, not a modelable line.

Market Reaction

• Pre-print setup: ABBV closed at $189.31 on July 30, entering the print up +6.5% YTD (from $177.70 at 2024 year-end), +2.2% on a trailing-12-month basis, and roughly flat over the trailing 30 days (−0.4%). The stock sat well within its 52-week closing range of $164.99–$216.66 — off the highs, not washed out. The S&P 500 entered the day +8.2% YTD, so ABBV was a market laggard heading in.
• Reaction-day move (BMO print, same session): ABBV gapped open +4.1% to $197.06 on the beat-and-raise, traded an intraday range of $187.62–$198.83, then faded steadily all day to close at $189.02, −0.2% (−$0.29) — essentially unchanged from the prior close. Volume of 10.3M ran 1.7x the 6.3M 30-day average. The S&P 500 closed −0.4% on the day, so ABBV's flat finish was a slight relative outperformance, but a stark round-trip from the open.

The price action is the most important non-fundamental data point in this report. A clean beat-and-raise — revenue and adjusted EPS both above consensus, the FY25 guide lifted for the second time, the marquee franchises raised — opened +4% and then gave the entire gap back to close flat. That round-trip, on elevated volume, is the textbook "sell the news" signature: the good news was already in the price, and the absence of a fresh catalyst (no refreshed long-term guide, two declining portfolios) gave fast money the cue to fade the pop.

Two specific elements likely capped the rally intraday. First, the aesthetics commentary — management conceding the consumer headwind is "more chronic" — landed as the one genuinely new and negative disclosure on the call, and it hit during Q&A as the stock was already off its opening high. Second, the full valuation: at the $197 opening print the stock was trading at ~16.4x the new FY25 EPS midpoint, a level at which a measured beat-and-raise simply does not offer enough surprise to sustain a 4% re-rating. The fade to flat is the market efficiently re-pricing a good-but-priced-in quarter.

Street Perspective

Debate: Is the Skyrizi/Rinvoq Engine Enough to Drive a Re-Rating From Here?

Bull view: Two best-in-class immunology assets pacing past $25B combined, both still gaining share, with IBD years behind psoriasis in penetration and a "third wave" of Rinvoq indications ($2B+ peak) coming. With no major LOE this decade, AbbVie can compound high-single to low-double-digit EPS for years — and the long-term guide is demonstrably conservative, setting up serial upgrades.

Bear view: The Street already knows all of this; it is why the stock trades at a premium to the large-cap pharma group, not a discount. The growth-drug strength is necessary just to offset Humira and fund the aesthetics/oncology soft spots, leaving the consolidated growth rate respectable but not exceptional. Law-of-large-numbers deceleration is the inevitable next chapter.

Our take: The bull case on the business is right and the bear case on the stock is also right — which is precisely a Hold. The franchise quality is not in question; the question is what you pay, and at ~16x with the upside telegraphed, the re-rating fuel is largely spent until the long-term guide is formally raised.

Debate: Is Aesthetics a Temporary Cyclical Trough or a Structurally Impaired Asset?

Bull view: Aesthetics is a market-leading, low-penetration, cash-pay category in a temporary consumer-spending air pocket. Botox holds dominant share, TrenibotE arrives in 2026, and the moment the consumer recovers, this snaps back to a growth contributor — AbbVie is buying it cheaply inside the conglomerate today.

Bear view: Management itself now calls the headwind "more chronic," concedes a "natural look" sentiment shift is permanently pressuring fillers, and can only defend share, not growth. This is a discretionary consumer business mis-housed inside a pharma multiple, and it is structurally dragging the consolidated growth and the stock's re-rating potential.

Our take: The bear has the better of it for the next several quarters. When management abandons the cyclical-recovery script, the burden of proof flips — we need to see an actual inflection before crediting one. At 8% of revenue it caps rather than breaks the thesis, but it is a real reason not to pay up.

Debate: Does the GAAP/Adjusted Gap and IPR&D-Heavy Model Deserve Scrutiny or a Pass?

Bull view: The GAAP-adjusted gap is just acquisition accounting — intangible amortization from Allergan/Cerevel/ImmunoGen plus IPR&D for a prolific, value-creating BD machine. Running IPR&D through adjusted EPS is actually more conservative than most peers, who exclude it. Cash flow funds the dividend and the deals; the model is sound.

Bear view: A $0.52 GAAP print against $2.97 adjusted is a $2.45 gap, and 30+ deals a year make the IPR&D drag a permanent, lumpy feature rather than a one-off. The "clean" guide that excludes future IPR&D will be reduced by deals all year — so the headline EPS range overstates what investors will actually realize.

Our take: We side with the bull on substance — including IPR&D in adjusted EPS is the more honest convention, and the BD cadence builds genuine long-duration value. But the bear's practical point stands: the reported number is noisier and the guide softer than the headline implies, which is one more reason a full multiple is hard to justify expanding from here.

Model & Valuation Framework

Valuation framework: At the $189.31 pre-print close, ABBV trades at approximately 15.8x the raised FY25 adjusted-EPS midpoint of $11.98 (~16.4x at the $197 opening pop). That is a premium to the diversified large-cap pharma peer group, which clusters in the low-teens, and reflects the market already crediting the superior Skyrizi/Rinvoq growth profile and the de-risked LOE. On forward FY26 EPS of ~$13.00–$13.50, the multiple compresses to ~14–14.5x — reasonable but not cheap for a high-single/low-double-digit grower carrying two declining portfolios.

Fair-value anchor / 12-month framing: We anchor fair value at roughly 15–16x forward (FY26) adjusted EPS, yielding a base-case range of ~$195–$215 (mid ~$205) — modest upside from the $189 spot, supplemented by a ~3.5% dividend yield. A bull case (aesthetics troughs, long-term guide formally raised at Q4/JPM, 17x forward) supports the high-$220s/low-$230s and approaches the 52-week high. A bear case (aesthetics deteriorates further, a 2026 tariff print, multiple compresses to 13x) supports the low-$170s/high-$160s, near the 52-week low. The resulting up/down is roughly symmetric — perhaps +10–15% to the bull, −10–12% to the bear — which, even with the dividend, does not clear the bar for Outperform versus the S&P 500. Hence Hold, with a constructive bias that would flip on a pullback toward the low-$180s or on a confirmed aesthetics trough.

Thesis Scorecard (Initiation)

As this is our initiating note, the scorecard establishes the bull and bear pillars we will track each quarter rather than grading against a prior framework.

Overall: The business thesis is strong and the operational quarter was good. But the investment thesis at this price is balanced: every confirmed bull pillar is matched by a confirmed bear pillar (full valuation, two declining portfolios), and the market's own verdict — a +4% gap sold back to flat — is the cleanest available read that the good news is already discounted.

Action: Initiate at Hold (constructive bias). We want to own this franchise at the right price. We would upgrade to Outperform on (a) a pullback toward the low-$180s that restores a margin of safety, (b) a confirmed aesthetics trough or stabilization, or (c) a formal upward revision to the long-term Skyrizi/Rinvoq guidance at the Q4/JPM update. We would move to Underperform on a meaningful aesthetics step-down combined with an adverse Section 232 outcome that the platform growth cannot earn through.

Bottom Line: A Great Business at a Fair Price

AbbVie's Q2 was the quarter the bull case needed: Skyrizi and Rinvoq pacing past $25B and still gaining share, neuroscience compounding in the mid-20s, the Humira cliff reduced to a known and fading number, and a second guidance raise of the year. If the only question were "is this a good company growing through the largest patent cliff in industry history?" the answer is an unambiguous yes, and the ex-Humira platform's 22% growth is the proof.

But the question for a new position is the price, and the tape answered it for us. A clean beat-and-raise that gaps +4% and closes flat is the market telling you the good news is in the stock. At ~16x the raised guide, with aesthetics in a headwind management now calls "more chronic," oncology dragging, and the most obvious upgrade catalyst (a refreshed long-term guide) deliberately deferred to year-end, the forward 12-month risk/reward versus the S&P 500 is balanced rather than skewed up.

We initiate coverage of AbbVie at Hold, with a clear constructive bias. This is a name we want to own — on a better entry, a troughed aesthetics line, or a formal long-term guide raise. Today, the platform is firing on all cylinders and the price already knows it.